Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents
Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 19966-19987
DOI: 10.1021/acs.jmedchem.4c01260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.11.2024. Verfasst von Zhiqiang Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutic…. Hauptthemen laut MEDLINE: Hyperuricemia, Xanthine Oxidase, Organic Anion Transporters. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, China Postdoctoral Science Foundation, Southern Medical University.
Abstract (Originalsprache)
Increased biosynthesis or underexcretion of uric acid (UA or urate) in the body ultimately leads to the development of hyperuricemia. Epidemiological studies indicate that hyperuricemia is closely associated with the occurrence of various diseases such as gout and cardiovascular diseases. Currently, the first-line therapeutic medications used to reduce UA levels primarily include xanthine oxidase (XO) inhibitors, which limit UA production, and urate transporter 1 (URAT1) inhibitors, which decrease urate reabsorption and enhance urate excretion. Despite significant progress in urate-lowering therapies, long-term use of these drugs can cause hepatorenal toxicity as well as cardiovascular complications. Therefore, there is an urgent need for novel anti-hyperuricemic agents with better efficacy and lower toxicity. This perspective mainly focuses on the current research progress and design strategy of anti-hyperuricemic agents, particularly those targeting XO and URAT1. It is our hope that this perspective will provide insights into the challenges and opportunities for anti-hyperuricemic drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Chengdu Easton Biopharmaceuticals Co., Ltd., Chengdu 611731, China.
ORCID-Profile: Zean Zhao, Xiaoxun Li, Jianxin Pang, Jianjun Chen
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- Southern Medical University
Zitieren
APA
Sun, Z., Zhang, X., Zhao, Z., Li, X., Pang, J., & Chen, J. (2024). Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents. Journal of Medicinal Chemistry, 67(22), 19966-19987. https://doi.org/10.1021/acs.jmedchem.4c01260
Vancouver
Sun Z, Zhang X, Zhao Z, Li X, Pang J, Chen J. Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents. Journal of Medicinal Chemistry. 2024;67(22):19966-19987. doi:10.1021/acs.jmedchem.4c01260
BibTeX
@article{Sun2024,
author = {Sun, Zhiqiang and Zhang, Xuewen and Zhao, Zean and Li, Xiaoxun and Pang, Jianxin and Chen, Jianjun},
title = {Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {22},
pages = {19966--19987},
doi = {10.1021/acs.jmedchem.4c01260}
}
EUVIMED